Unità di Bioetica, Presidenza, Istituto Superiore di Sanità, Via Giano della Bella 34, Rome, Italy.
Ann Ist Super Sanita. 2011;47(4):353-62. doi: 10.4415/ANN_11_04_06.
This article addresses the ethical requirements to be considered when conducting clinical trials involving human subjects whose mental condition limits their ability to understand the information and to express fully autonomous and informed consent. It does not address other categories of vulnerable persons, such as children, or advanced directives concerning end-of-life care. There are many ethical issues entailed in clinical trials involving subjects with mental disabilities: how to obtain informed consent, balancing risks and benefits, balancing individual benefits with collective scientific and social interests, legal representation and many more. This article focuses on the issues surrounding the concept of minimal risk and the relationship between informed consent and risk. These issues are addressed with particular emphasis on the regulations adopted by the European Union and the federal government of the United States of America. The conclusion proposes a list of working criteria.
本文针对涉及精神状况限制其理解信息和充分自主表达知情同意能力的人类受试者的临床试验,提出了需要考虑的伦理要求。本文不涉及其他弱势群体,如儿童,或临终关怀的预先指示。涉及精神残疾受试者的临床试验涉及许多伦理问题:如何获得知情同意,平衡风险和收益,平衡个人利益与集体科学和社会利益,法律代表等等。本文重点讨论了与最小风险概念以及知情同意与风险之间关系相关的问题。这些问题特别强调了欧盟和美利坚合众国联邦政府所通过的规定。结论提出了一份工作标准清单。